{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"787.53","value":"1238.1"},{"groupId":"OG001","spread":"889.39","value":"2070.0"},{"groupId":"OG002","spread":"1709.15","value":"2873.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"100"}],"units":"Participants"}],"title":"Duvelisib: Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1019.10","value":"1492.5"},{"groupId":"OG002","spread":"1336.94","value":"2648.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"68"}],"units":"Participants"}],"title":"Duvelisib: Cycle 2, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1408.99","value":"1310.4"},{"groupId":"OG001","spread":"772.13","value":"1580.9"},{"groupId":"OG002","spread":"1919.33","value":"2387.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"100"}],"units":"Participants"}],"title":"Metabolite (IPI-156): Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"441.55","value":"894.8"},{"groupId":"OG002","spread":"1655.89","value":"2427.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"68"}],"units":"Participants"}],"title":"Metabolite (IPI-156): Cycle 2, Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"100"}],"units":"Participants"}],"description":"Blood samples were taken for the analyses of duvelisib and IPI-656 in plasma at designated time points. Results are reported as nanograms/milliliter (ng/mL).","dispersionType":"Standard Deviation","groups":[{"description":"Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-participant basis to 50 mg and then 75 mg, based on the participant's response to and tolerance of therapy, in 28-day cycles.","id":"OG000","title":"Dose Optimization Phase: Cohort 1"},{"description":"Duvelisib 75 mg PO BID, administered in 28-day cycles.","id":"OG001","title":"Dose Optimization Phase: Cohort 2"},{"description":"Duvelisib PO BID at a starting dose of 75 mg for the first 2 cycles, followed by a mandatory reduction to 25 mg BID thereafter for those participants with CR, PR or SD, in 28-day cycles (dose determined in Optimization Phase).","id":"OG002","title":"Expansion Phase"}],"paramType":"MEAN","populationDescription":"Safety Analysis Set: all participants who received at least one dose of study drug. Here, 'Overall Number of Participants Analyzed' signifies those who were evaluable for this outcome measure, and 'Number Analyzed' signifies those participants who were evaluable for this outcome measure at the specified time points.","reportingStatus":"POSTED","timeFrame":"Day 15 of Cycles 1 and 2 (4 hours postdose) (28-day cycles)","title":"Plasma Concentration of IPI-145 (Duvelisib) and IPI-656 (Metabolite)","type":"SECONDARY","unitOfMeasure":"ng/mL"}